An innovative medical device company based in Israel developed a unique ocular implant with an artificial endothelial layer to treat patients with corneal edema caused by a dysfunctional endothelial layer, resulting in poor vision quality.

Nextvel was involved in the early-stage clinical development and pilot clinical investigation. When the Phase 2 study was conducted across multiple countries, Nextvel provided regulatory and clinical trial management support for India. Nextvel facilitated patient enrolment within the stipulated time frame, achieving the fastest enrolment rate among participating countries. The one-year follow-up study had a 90% subject retention rate in India at the end of 12 months follow-up period. Nextvel used the latest EDC and Document Management System for seamless data management for this project.